The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

A group of 13 Democratic House Representatives introduced a package of eight bills last week that would crack down on Medicare Advantage and strengthen traditional Medicare. The package was introduced ...

Function Health raised a $298 million Series B round, pushing its valuation into unicorn territory at $2.5 billion. The ...

Like many startups, Oura’s mission has evolved over the years. It began as a sleep-focused wellness startup and has now grown into an $11 billion company carving out a role in health improvement and ...

Ostro’s effort to boost the country’s less-than-stellar health literacy earned the startup a place in the Guinness World Records this week. The company’s virtual course now holds the record for the ...

The CDC has caused outrage from many in the medical community after changing its webpage on Wednesday to include language that links vaccines to autism, despite numerous studies showing that there’s ...

GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive ...

Vaginal discomfort is one of the most common reasons women seek healthcare advice, but standard care isn’t always meeting patients’ needs. That’s why Evvy, a vaginal microbiome startup, has launched a ...

Pyx Health, a healthcare member activation company, launched a new platform on Monday to support care navigation and make it easier for people to access healthcare resources. Tucson, Arizona-based Pyx ...

Novartis has made kidney disorders an area of focus, and it’s now adding a new drug prospect through a deal to acquire Regulus Therapeutics, a biotech with a drug ready for pivotal testing in a rare ...

Running a dental practice involves numerous decisions, but few are as impactful as selecting a reliable supply partner. Who you choose may directly affect your center’s clinical operations, patient ...

Sanofi has reached a deal to acquire all of biologics drug developer Inhibrx, but the pharmaceutical giant will keep just a single drug candidate. The rest of Inhibrx’s assets will be spun off into a ...